Probiocon Gmbh

Synimmune Gmbh

Other

Baliopharm Ag

Julius-Maximilians-Universitat Wurzburg

Jung, Gundram

Ludger Grosse-Hovest

Andreas Herrmann

Helmut Salih

Gundram Jung

Hans-Georg Kopp

Stefanie Maurer

Martin Hofmann

Hans-Joerg Buehring

Berit Lochmann

Michael Durben

Steffen Aulwurm

Grundram Jung

Hans-Jörg Bühring

Gernot Stuhler

The invention provides for a RANKL-specific antagonistic agent recognizing human platelet-expressed receptor activator of nuclear factor kappa-B ligand (pRANKL), for use in treating a cancer patient to prevent or reduce premetastatic lesions in blood.

RANKL-specific agent for treating metastatic disease

A bispecific antibody format, which comprises a) a Fab fragment comprising a first binding site for a first antigen; b) an scFv fragment comprising a second binding site for a second antigen; and c) a CH2 domain, wherein the Fab fragment and the scFv fragment are linked via the CH2 domain, wherein the first antigen is CD95 and the second antigen is CD20; or the first antigen is CD20 and the second antigen is CD95.

Recombinant bispecific antibody binding to CD20 and CD95

The present invention relates to a bispecific antibody molecule, as well as a method for producing the same, its use and a nucleic acid molecule encoding the bispecific antibody molecule. The invention in particular provides an antibody molecule that is capable of mediating target cell restricted activation of immune cells.

Bispecific antibody molecule

A bispecific antibody format devoid of an active Fc moiety comprising a monovalent binding site for a death receptor and at least one binding site for a cell surface antigen expressed on B-cells, for use in the treatment or prevention of B cell mediated autoimmune diseases.

Methods of using bi-specific antibodies for treating B-cell-mediated autoimmune diseases or auto-reactive B-cells

The present invention relates to anti-FLT3 antibodies with a modified Fc region comprising the amino acid substitutions 239D and 332E to enhance antibody-dependent cell cytotoxicity (ADCC) of these antibodies. The invention further relates to pharmaceutical compositions containing these antibodies, nucleic acids encoding these antibodies as well as methods of using such antibodies.

Anti-FLT3 antibodies

Growing community of inventors

Tübingen, Germany

Ludger Grosse-Hovest